CD274 and non-small cell lung carcinoma: Currently, pembrolizumab in combination with chemotherapy is the preferred first-line regimen according to NCCN guidelines for patients with oncogenic driver negative NS-NSCLC and without contraindications to PD-1/PD-L1 inhibitors, regardless of PD-L1 expression level.